ClinicalTrials.gg
CompletedNCT06625827Updated Oct 3, 2024

A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)

A Phase 1 interventional study of Digoxin and Nemtabrutinib in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 9 months ago, and no results have been posted to the registry.
  • Registered 10 months after the study started (first participant enrolled Nov 2023, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The goal of the study is to learn what happens to levels of digoxin in a healthy person's body over time. Researchers will compare what happens to digoxin in the body when it is given with and without another medicine called nemtabrutinib. Researchers are testing if digoxin levels in the body are different when digoxin is given with or without nemtabrutinib.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is in good health based on medical history, physical examination, vital signs (VS) measurements, (ECGs), and laboratory safety tests performed before randomization
  • Has a (BMI) 18.0 to 32.0 kg/m\^2 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Has a medical history that may confound the results of the study or poses an additional risk to the participant in the study
  • Has a to digoxin and/or to other digitalis preparations including inactive ingredients (eg, lactose, corn starch and potato starch)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Digoxin

    Participants receive a single oral dose of digoxin (Treatment A).

    Drug: Digoxin

  • Experimental
    Digoxin + Nemtabrutinib

    Participants receive a single oral dose of digoxin coadministered with a single oral dose of nemtabrutinib (Treatment B).

    Drug: Digoxin · Drug: Nemtabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Digoxin

    Blood samples will be collected to determine the AUC0-Inf of digoxin.

    Time frame: At designated timepoints (up to approximately 7 days)

Secondary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Digoxin

    Blood samples will be collected to determine the AUC0-Last of digoxin.

    Time frame: At designated timepoints (up to approximately 7 days)

  2. Maximum Plasma Concentration (Cmax) of Digoxin

    Blood samples will be collected to determine the Cmax of digoxin.

    Time frame: At designated timepoints (up to approximately 7 days)

  3. Plasma Concentration 24 Hours Postdose (C24) of Digoxin

    Blood samples will be collected to determine the C24 of digoxin.

    Time frame: At designated timepoints (up to approximately 24 hours)

  4. Time to Maximum Plasma Concentration (Tmax) of Digoxin

    Blood samples will be collected to determine the Tmax of digoxin.

    Time frame: Predose and at designated timepoints (up to approximately 7 days)

  5. Apparent Terminal Half-life (t1/2) of Digoxin

    Blood samples will be collected to determine t1/2 of digoxin.

    Time frame: At designated timepoints (up to approximately 7 days)

  6. Apparent Clearance (CL/F) of Digoxin

    Blood samples will be collected to determine the CL/F of digoxin.

    Time frame: At designated timepoints (up to approximately 7 days)

  7. Apparent Volume of Distribution (Vz/F) of Digoxin

    Blood samples will be collected to determine the Vz/F of digoxin.

    Time frame: At designated timepoints (up to approximately 7 days)

  8. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 8 weeks

  9. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported.

    Time frame: Up to approximately 8 weeks

07

Study locations

1 site
  • ICON (Site 0001)
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Jan 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 3, 2024
StartActual
Nov 7, 2023
Primary completionActual
Jan 22, 2024
CompletionActual
Jan 22, 2024
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06625827
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Nov 7, 2023
Primary completion
Jan 22, 2024
Completion
Jan 22, 2024
Last update
Oct 3, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Digoxin · ARQ531

Start the discussion